Quantitative  ||| S:0 E:13 ||| JJ
mass  ||| S:13 E:18 ||| NN
spectrometric  ||| S:18 E:32 ||| NN
immunoassay  ||| S:32 E:44 ||| NN
for  ||| S:44 E:48 ||| IN
the  ||| S:48 E:52 ||| DT
chemokine  ||| S:52 E:62 ||| JJ
RANTES  ||| S:62 E:69 ||| NNP
and  ||| S:69 E:73 ||| CC
its  ||| S:73 E:77 ||| PRP$
variants  ||| S:77 E:86 ||| NNS
The  ||| S:86 E:90 ||| DT
chemokine  ||| S:90 E:100 ||| JJ
RANTES  ||| S:100 E:107 ||| NNP
plays  ||| S:107 E:113 ||| VBZ
a  ||| S:113 E:115 ||| DT
key  ||| S:115 E:119 ||| JJ
role  ||| S:119 E:124 ||| NN
in  ||| S:124 E:127 ||| IN
inflammation ||| S:127 E:139 ||| NN
,  ||| S:139 E:141 ||| ,
cell  ||| S:141 E:146 ||| NN
recruitment  ||| S:146 E:158 ||| NN
and  ||| S:158 E:162 ||| CC
T  ||| S:162 E:164 ||| NN
cell  ||| S:164 E:169 ||| NN
activation ||| S:169 E:179 ||| NN
.  ||| S:179 E:181 ||| .
RANTES  ||| S:181 E:188 ||| NNP
is  ||| S:188 E:191 ||| VBZ
heterogenic  ||| S:191 E:203 ||| VBN
and  ||| S:203 E:207 ||| CC
exists  ||| S:207 E:214 ||| VBZ
as  ||| S:214 E:217 ||| RB
multiple  ||| S:217 E:226 ||| JJ
variants  ||| S:226 E:235 ||| NN
in  ||| S:235 E:238 ||| IN
vivo ||| S:238 E:242 ||| NN
.  ||| S:242 E:244 ||| .
Herein  ||| S:244 E:251 ||| VBG
we  ||| S:251 E:254 ||| PRP
describe  ||| S:254 E:263 ||| VBP
the  ||| S:263 E:267 ||| DT
development  ||| S:267 E:279 ||| NN
and  ||| S:279 E:283 ||| CC
characterization  ||| S:283 E:300 ||| NN
of  ||| S:300 E:303 ||| IN
a  ||| S:303 E:305 ||| DT
fully  ||| S:305 E:311 ||| RB
quantitative  ||| S:311 E:324 ||| JJ
mass  ||| S:324 E:329 ||| NN
spectrometric  ||| S:329 E:343 ||| NN
immunoassay  ||| S:343 E:355 ||| NNS
( ||| S:355 E:356 ||| -LRB-
MSIA ||| S:356 E:360 ||| NNP
)  ||| S:360 E:362 ||| -RRB-
for  ||| S:362 E:366 ||| IN
analysis  ||| S:366 E:375 ||| NN
of  ||| S:375 E:378 ||| IN
intact  ||| S:378 E:385 ||| JJ
RANTES  ||| S:385 E:392 ||| NNP
and  ||| S:392 E:396 ||| CC
its  ||| S:396 E:400 ||| PRP$
proteoforms  ||| S:400 E:412 ||| NN
in  ||| S:412 E:415 ||| IN
human  ||| S:415 E:421 ||| JJ
serum  ||| S:421 E:427 ||| NN
and  ||| S:427 E:431 ||| CC
plasma  ||| S:431 E:438 ||| JJ
samples ||| S:438 E:445 ||| NNS
.  ||| S:445 E:447 ||| .
The  ||| S:447 E:451 ||| DT
assay  ||| S:451 E:457 ||| NN
exhibits  ||| S:457 E:466 ||| VBZ
linearity  ||| S:466 E:476 ||| VBN
over  ||| S:476 E:481 ||| IN
a  ||| S:481 E:483 ||| DT
wide  ||| S:483 E:488 ||| JJ
concentration  ||| S:488 E:502 ||| NN
range  ||| S:502 E:508 ||| NN
( ||| S:508 E:509 ||| -LRB-
1.56-200ng ||| S:509 E:519 ||| NNP
/ ||| S:519 E:520 ||| NNP
mL ||| S:520 E:522 ||| NNP
) ||| S:522 E:523 ||| -RRB-
,  ||| S:523 E:525 ||| ,
intra-  ||| S:525 E:532 ||| JJ
and  ||| S:532 E:536 ||| CC
inter-assay  ||| S:536 E:548 ||| JJ
precision  ||| S:548 E:558 ||| NN
with  ||| S:558 E:563 ||| IN
CVs  ||| S:563 E:567 ||| JJ
< ||| S:567 E:568 ||| SYM
10 ||| S:568 E:570 ||| CD
% ||| S:570 E:571 ||| NN
,  ||| S:571 E:573 ||| ,
and  ||| S:573 E:577 ||| CC
good  ||| S:577 E:582 ||| JJ
linearity  ||| S:582 E:592 ||| NN
and  ||| S:592 E:596 ||| CC
recovery  ||| S:596 E:605 ||| NN
correlations ||| S:605 E:617 ||| NN
.  ||| S:617 E:619 ||| .
The  ||| S:619 E:623 ||| DT
assay  ||| S:623 E:629 ||| NN
was  ||| S:629 E:633 ||| VBD
tested  ||| S:633 E:640 ||| VBN
in  ||| S:640 E:643 ||| IN
different  ||| S:643 E:653 ||| JJ
biological  ||| S:653 E:664 ||| JJ
matrices ||| S:664 E:672 ||| NN
,  ||| S:672 E:674 ||| ,
and  ||| S:674 E:678 ||| CC
it  ||| S:678 E:681 ||| PRP
was  ||| S:681 E:685 ||| VBD
benchmarked  ||| S:685 E:697 ||| VBN
against  ||| S:697 E:705 ||| IN
an  ||| S:705 E:708 ||| DT
existing  ||| S:708 E:717 ||| JJ
RANTES  ||| S:717 E:724 ||| NNP
ELISA ||| S:724 E:729 ||| NNP
.  ||| S:729 E:731 ||| .
The  ||| S:731 E:735 ||| DT
new  ||| S:735 E:739 ||| JJ
RANTES  ||| S:739 E:746 ||| NNP
MSIA  ||| S:746 E:751 ||| NNP
was  ||| S:751 E:755 ||| VBD
used  ||| S:755 E:760 ||| VBN
to  ||| S:760 E:763 ||| TO
analyze  ||| S:763 E:771 ||| VB
RANTES  ||| S:771 E:778 ||| NNP
and  ||| S:778 E:782 ||| CC
its  ||| S:782 E:786 ||| PRP$
proteoforms  ||| S:786 E:798 ||| NN
in  ||| S:798 E:801 ||| IN
a  ||| S:801 E:803 ||| DT
small  ||| S:803 E:809 ||| JJ
clinical  ||| S:809 E:818 ||| JJ
cohort ||| S:818 E:824 ||| NN
,  ||| S:824 E:826 ||| ,
revealing  ||| S:826 E:836 ||| VBG
the  ||| S:836 E:840 ||| DT
quantitative  ||| S:840 E:853 ||| JJ
distribution  ||| S:853 E:866 ||| NN
and  ||| S:866 E:870 ||| CC
frequency  ||| S:870 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
the  ||| S:883 E:887 ||| DT
native  ||| S:887 E:894 ||| NN
and  ||| S:894 E:898 ||| CC
truncated  ||| S:898 E:908 ||| FW
RANTES  ||| S:908 E:915 ||| FW
proteoforms ||| S:915 E:926 ||| FW
.  ||| S:926 E:928 ||| .
In  ||| S:928 E:931 ||| IN
the  ||| S:931 E:935 ||| DT
last  ||| S:935 E:940 ||| JJ
two  ||| S:940 E:944 ||| CD
decades ||| S:944 E:951 ||| NNS
,  ||| S:951 E:953 ||| ,
RANTES  ||| S:953 E:960 ||| NNP
has  ||| S:960 E:964 ||| VBZ
been  ||| S:964 E:969 ||| VBN
studied  ||| S:969 E:977 ||| VBN
extensively  ||| S:977 E:989 ||| RB
due  ||| S:989 E:993 ||| JJ
to  ||| S:993 E:996 ||| TO
its  ||| S:996 E:1000 ||| PRP$
association  ||| S:1000 E:1012 ||| NN
with  ||| S:1012 E:1017 ||| IN
numerous  ||| S:1017 E:1026 ||| JJ
clinical  ||| S:1026 E:1035 ||| JJ
conditions ||| S:1035 E:1045 ||| NNS
,  ||| S:1045 E:1047 ||| ,
including  ||| S:1047 E:1057 ||| VBG
kidney-related ||| S:1057 E:1071 ||| JJ
,  ||| S:1071 E:1073 ||| ,
autoimmune ||| S:1073 E:1083 ||| NN
,  ||| S:1083 E:1085 ||| ,
cardiovascular ||| S:1085 E:1099 ||| JJ
,  ||| S:1099 E:1101 ||| ,
viral  ||| S:1101 E:1107 ||| JJ
and  ||| S:1107 E:1111 ||| CC
metabolic  ||| S:1111 E:1121 ||| JJ
pathologies ||| S:1121 E:1132 ||| NN
.  ||| S:1132 E:1134 ||| .
Although  ||| S:1134 E:1143 ||| IN
a  ||| S:1143 E:1145 ||| DT
single  ||| S:1145 E:1152 ||| JJ
gene  ||| S:1152 E:1157 ||| NN
product ||| S:1157 E:1164 ||| NN
,  ||| S:1164 E:1166 ||| ,
RANTES  ||| S:1166 E:1173 ||| NNP
is  ||| S:1173 E:1176 ||| VBZ
expressed  ||| S:1176 E:1186 ||| VBN
in  ||| S:1186 E:1189 ||| IN
a  ||| S:1189 E:1191 ||| DT
range  ||| S:1191 E:1197 ||| NN
of  ||| S:1197 E:1200 ||| IN
cells  ||| S:1200 E:1206 ||| NNS
and  ||| S:1206 E:1210 ||| CC
tissues  ||| S:1210 E:1218 ||| NNS
presenting  ||| S:1218 E:1229 ||| VBG
with  ||| S:1229 E:1234 ||| IN
different  ||| S:1234 E:1244 ||| JJ
endogenously  ||| S:1244 E:1257 ||| NN
produced  ||| S:1257 E:1266 ||| VBD
variants  ||| S:1266 E:1275 ||| JJ
and  ||| S:1275 E:1279 ||| CC
PTMs ||| S:1279 E:1283 ||| JJ
.  ||| S:1283 E:1285 ||| .
The  ||| S:1285 E:1289 ||| DT
structural  ||| S:1289 E:1300 ||| JJ
variety  ||| S:1300 E:1308 ||| NN
and  ||| S:1308 E:1312 ||| CC
population  ||| S:1312 E:1323 ||| NN
diversity  ||| S:1323 E:1333 ||| NN
that  ||| S:1333 E:1338 ||| WDT
has  ||| S:1338 E:1342 ||| VBZ
been  ||| S:1342 E:1347 ||| VBN
identified  ||| S:1347 E:1358 ||| VBN
for  ||| S:1358 E:1362 ||| IN
RANTES  ||| S:1362 E:1369 ||| NNP
necessitate  ||| S:1369 E:1381 ||| VBZ
developing  ||| S:1381 E:1392 ||| VBG
advanced  ||| S:1392 E:1401 ||| JJ
methodologies  ||| S:1401 E:1415 ||| NNS
that  ||| S:1415 E:1420 ||| WDT
can  ||| S:1420 E:1424 ||| MD
provide  ||| S:1424 E:1432 ||| VB
insight  ||| S:1432 E:1440 ||| VBN
into  ||| S:1440 E:1445 ||| IN
the  ||| S:1445 E:1449 ||| DT
protein  ||| S:1449 E:1457 ||| NN
heterogeneity  ||| S:1457 E:1471 ||| NNS
and  ||| S:1471 E:1475 ||| CC
its  ||| S:1475 E:1479 ||| PRP$
function  ||| S:1479 E:1488 ||| NN
and  ||| S:1488 E:1492 ||| CC
regulation  ||| S:1492 E:1503 ||| NN
in  ||| S:1503 E:1506 ||| IN
disease ||| S:1506 E:1513 ||| NN
.  ||| S:1513 E:1515 ||| .
In  ||| S:1515 E:1518 ||| IN
this  ||| S:1518 E:1523 ||| DT
work  ||| S:1523 E:1528 ||| NN
we  ||| S:1528 E:1531 ||| PRP
present  ||| S:1531 E:1539 ||| VBP
a  ||| S:1539 E:1541 ||| DT
simple ||| S:1541 E:1547 ||| JJ
,  ||| S:1547 E:1549 ||| ,
efficient  ||| S:1549 E:1559 ||| JJ
and  ||| S:1559 E:1563 ||| CC
high-throughput  ||| S:1563 E:1579 ||| JJ
mass  ||| S:1579 E:1584 ||| NN
spectrometric  ||| S:1584 E:1598 ||| NN
immunoassay  ||| S:1598 E:1610 ||| NNS
( ||| S:1610 E:1611 ||| -LRB-
MSIA ||| S:1611 E:1615 ||| NNP
)  ||| S:1615 E:1617 ||| -RRB-
method  ||| S:1617 E:1624 ||| NN
for  ||| S:1624 E:1628 ||| IN
analysis  ||| S:1628 E:1637 ||| NN
of  ||| S:1637 E:1640 ||| IN
RANTES  ||| S:1640 E:1647 ||| NNP
proteoforms ||| S:1647 E:1658 ||| NN
.  ||| S:1658 E:1660 ||| .
RANTES  ||| S:1660 E:1667 ||| NNP
MSIA  ||| S:1667 E:1672 ||| NNP
can  ||| S:1672 E:1676 ||| MD
detect  ||| S:1676 E:1683 ||| VB
and  ||| S:1683 E:1687 ||| CC
analyze  ||| S:1687 E:1695 ||| VB
RANTES  ||| S:1695 E:1702 ||| JJ
proteoforms  ||| S:1702 E:1714 ||| NN
and  ||| S:1714 E:1718 ||| CC
provide  ||| S:1718 E:1726 ||| VB
an  ||| S:1726 E:1729 ||| DT
insight  ||| S:1729 E:1737 ||| NN
into  ||| S:1737 E:1742 ||| IN
the  ||| S:1742 E:1746 ||| DT
endogenous  ||| S:1746 E:1757 ||| JJ
protein  ||| S:1757 E:1765 ||| NN
modifications ||| S:1765 E:1778 ||| NNS
.  ||| S:1778 E:1780 ||| .
